<DOC>
	<DOCNO>NCT00440674</DOCNO>
	<brief_summary>The primary objective study evaluate safety effectiveness direct stenting technique compare conventional stenting pre-dilatation strategy use CoStar Paclitaxel-eluting coronary stent system treatment single de novo lesion native coronary artery ≤ 25 mm long native coronary artery 2.5-3.5 mm diameter .</brief_summary>
	<brief_title>Prospective , Multi-Center , Random . Study CoStar Paclitaxel-Eluting Coronary Stent ( Direct Stenting vs. Pre-Dilatation )</brief_title>
	<detailed_description>Prospective , multi-center , randomize ( 1:1 ) , open-label study evaluate direct stenting compare conventional stenting pre-dilatation strategy treatment single de novo Lesion single native coronary artery patient undergo elective percutaneous coronary intervention .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Dilatation , Pathologic</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Eligible percutaneous coronary intervention Documented stable unstable angina pectoris document ischemia , document silent ischemia Left ventricular ejection fraction ( LVEF ) ≥25 % document within last 6 week Acceptable candidate coronary artery bypass graft surgery Single target vessel / single target lesion treat Target lesion may compose multiple lesion must completely coverable one ( 1 ) study stent Cumulative target lesion length per vessel ≤ 25 mm RVD 2.53.5 mm Target lesion diameter stenosis ≥ 50 % &lt; 100 % Target vessel undergone prior revascularization within precede 6 month Known sensitivity cobalt chromium , Paclitaxel PLGA Acute MI within 72 hour prior index procedure define presence new pathologic Qwave , creatine kinase ( CK ) level &gt; 2x laboratory upper limit normal elevate MB The patient cardiogenic shock Cerebrovascular Accident ( CVA ) within past 6 month Acute chronic renal dysfunction ( creatinine &gt; 2.0 mg/dL &gt; 150 µmol/L ) / Contraindication ASA Clopidogrel Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) Active gastrointestinal ( GI ) bleed within past three month Any prior true anaphylactic reaction contrast agent Patient currently take Colchicine Patient currently , treat Paclitaxel ( systemic ) within12 month index procedure Comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study Left main coronary artery disease ( stenosis &gt; 50 % ) , whether protect unprotected . Target lesion involve bifurcation diseased ( &gt; 50 % stenotic ) branch vessel &gt; 2.0 mm diameter require intervention . Target lesion totally occluded Thrombolysis In MI ( TIMI flow ≤1 ) . The target vessel prior drugeluting stent placement vessel segment ( branch ) proximal intend target lesion site . Angiographic restenosis segment target vessel undergone prior PCI . Angiographic evidence atherosclerotic disease &gt; 50 % diameter stenosis ( visual estimate ) proximal distal target lesion ( applies major epicardial portion target vessel contiguous vessel segment target lesion locate branch vessel )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Direct Stenting</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Pre-dilatation</keyword>
	<keyword>Drug-eluting stent</keyword>
</DOC>